25 Years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines

Clinical and Experimental Immunology

Volumn 154, Issue 1, 2008, Pages 6-14

  Scherer, E ^a,b   Douek, D ^c   McMichael, A ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV; Immunopathogenesis; Meeting; Restriction; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; CONFERENCE PAPER; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DISEASE COURSE; DNA SEQUENCE; ENZYME ACTIVITY; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; UBIQUITINATION; VIROLOGY; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENES, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HIV; HIV INFECTIONS; HUMANS;

EID: 51349099920     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03750.x     Document Type: Conference Paper

References (38)

1. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a t-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983 220 : 868 71.
2. Gallo RC, Sarin PS, Gelmann EP et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983 220 : 865 7.
3. Van Heuverswyn F, Peeters M. The origins of HIV and implications for the global epidemic. Curr Infect Dis Rep 2007 9 : 338 46.
4. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 2008 152 : 201 10.
5. Sagata N, Yasunaga T, Tsuzuku-Kawamura J, Ohishi K, Ogawa Y, Ikawa Y. Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses. Proc Natl Acad Sci USA 1985 82 : 677 81.
6. Pantaleo G, Graziosi C, Butini L et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991 88 : 9838 42.
7. Veazey RS, DeMaria M, Chalifoux LV et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998 280 : 427 31.
8. Brenchley JM, Schacker TW, Ruff LE et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004 200 : 749 59.
9. Arhel NJ, Souquere-Besse S, Munier S et al. HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J 2007 26 : 3025 37.
10. Yu Z, Gonciarz MD, Sundquist WI, Hill CP, Jensen GJ. Cryo-EM structure of dodecameric Vps4p and its 2:1 complex with Vta1p. J Mol Biol 2008 377 : 364 77.
11. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007 81 : 1000 12.
12. Arthos J, Cicala C, Martinelli E et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008 9 : 301 9.
13. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007 282 : 2587 95.
14. Triboulet R, Mari B, Lin YL et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007 315 : 1579 82.
15. Campbell EM, Perez O, Anderson JL, Hope TJ. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 2008 180 : 549 61.
16. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984 101 : 421 8.
17. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 12 : 1365 71.
18. Gordon SN, Klatt NR, Bosinger SE et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007 179 : 3026 34.
19. Pandrea IV, Gautam R, Ribeiro RM et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007 179 : 3035 46.
20. Diop OM, Ploquin MJ, Mortara L et al. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol 2008 82 : 5145 52.
21. Miller CJ, Li Q, Abel K et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005 79 : 9217 27.
22. Pereyra F, Addo MM, Kaufmann DE et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008 197 : 563 71.
23. Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007 317 : 944 7.
24. Alter G, Martin MP, Teigen N et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007 204 : 3027 36.
25. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telenti A. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 2006 3 : 11.
26. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005 307 : 1434 40.
27. Letvin NL, Mascola JR, Sun Y et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006 312 : 1530 3.
28. Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001 75 : 8340 7.
29. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 6 : 207 10.
30. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 449 : 101 4.
31. Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 11 : 615 22.
32. Trkola A, Kuster H, Rusert P et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008 82 : 1591 9.
33. Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007 445 : 732 7.
34. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003 77 : 5889 901.
35. Betts MR, Nason MC, West SM et al. HIV nonprogressorspreferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006 107 : 4781 9.
36. Letourneau S, Im EJ, Mashishi T et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007 2 : e984.
37. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007 369 : 643 56.
38. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007 369 : 657 66.